Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUR-1008 vs Kreon in exocrine pancreatic insufficiency associated with cystic fibrosis (crossover)
2009-012842-21Phase 3Completed
- Sponsor
- Aptalis Pharma Inc.
- Start
- Jun 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pancrelipase in exocrine pancreatic insufficiency (EPI) (2 arms), sponsored by Aptalis Pharma Inc. Primary endpoint: Coefficient of fat absorption (CFA). Started Jun 2010; status: completed.
02
Drugs
pancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2009-012842-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012842-21.